Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns whether Cassava has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 18, 2022, The New York Times published an article entit

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm

As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.

The Crowd Has Wisely Soured on Cassava Sciences Stock

The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.

Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report.

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?

Why Is Cassava Sciences (SAVA) Stock Down Today?

The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.

Cassava Sciences Is Worth Considering After Hitting Its Latest Trough

Cassava Sciences is trading near its 52 week lows.

3 Key Points To Remember About Cassava Sciences

– All Stakeholder Are Welcome to Listen by Webcast –

Webcast Details for Cassava Sciences' Upcoming Fireside Chat

It helps to have plenty of cold, hard cash.

Here's Why Cassava Sciences Stock Could Make a Comeback

SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.

Risk-on Biotech Investors Should Buy Cassava Sciences

– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates –

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness, you may find now to be the right time to initiate a position.

Keep Risk in Mind With Cassava Sciences Stock, but Don't Dismiss Upside Potential

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.

Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days

AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session.

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. The post Why Cassava Sciences Is Still a High-Risk Play appeared first on InvestorPlace.

Why Cassava Sciences Is Still a High-Risk Play

The FDA Deals Another Blow To Cassava Sciences' Bears

After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen Petitions Filed on Behalf of Short Selling Clients.

Here is where you can Cassava Sciences stock (SAVA): it is up 7% today

AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney on behalf of short-selling clients. FDA also denied four supplements to the August 2021 Citizen Petition. FDA also denied a September 2021 Citizen Petition, and a supplement, that were also filed by the same attorney on behalf of short-selling clients.

FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients

Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows.

Does Cassava Sciences and Its Alzheimer's Drug Really Have What It Takes?

As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. The post Keep an Eye on $60 as a Target Price for Cassava Sciences appeared first on InvestorPlace.

Keep an Eye on $60 as a Target Price for Cassava Sciences

Vinco Ventures

Biofrontera

Sirius XM Holdings Inc

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More

SAVA stock will continue to trade sideways until the moment of truth arrives for its drug candidate Simufilam. The post The End Result May Be Worth the Wait With Cassava Sciences Stock appeared first on InvestorPlace.

The End Result May Be Worth the Wait With Cassava Sciences Stock

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $45.73, moving -0.61% from the previous trading session.

News for Cassava Sciences Inc Stock (SAVA)